Portal de Periódicos da CAPES

A mutation associated with clofazimine and bedaquiline cross-resistance in MDR-TB following bedaquiline treatment

2014; European Respiratory Society; Volume: 45; Issue: 2 Linguagem: Inglês

10.1183/09031936.00142914

1399-3003

Ákos Somoskövi, Vera Bruderer, Rico Hömke, Guido V. Bloemberg, Erik C. Böttger,

Mycobacterium research and diagnosis

The world-wide increase in the incidence of multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB) poses a major clinical challenge. The treatment outcome of MDR-TB and XDR-TB patients is often poor and unsuccessful in the absence of an optimal number of active drugs [1]. Novel antituberculous compounds are urgently required and only very few, such as bedaquiline, have recently been approved for tuberculosis treatment [2]. In a recent phase 2b clinical trial that was based on a 160 newly diagnosed MDR-TB patients, the addition of bedaquiline to a preferred background regimen for 24 weeks resulted in faster culture conversion and significantly more culture conversion at 120 weeks compared with the control group. However, there were more deaths in the bedaquiline than in the placebo group and half of these patients died due to tuberculosis. So far, it is unclear whether the death of any of these patients may have been associated with diminished susceptibility to bedaquiline [3]. Acquired clofazimine and bedaquiline cross-resistance in a patient due to mutation in the M. tuberculosis Rv0678 gene